The US Food and Drug Administration (FDA) has permitted Pear Therapeutics to market the mobile medical application, Reset, to aid substance use disorder (SUD) treatment.

The Reset mobile medical application system is indicated for alcohol, cocaine, marijuana and stimulant SUDs, but not for treatment of opioid dependence.

Designed to be used in conjunction with outpatient therapy and a contingency management system commonly used to treat SUDs, the Reset features a patient application and clinician dashboard.

The device provides cognitive behavioural therapy to patients by teaching skills that help to enhance abstinence from substance abuse and elevate retention of outpatient therapy programmes.

FDA Centre for Devices and Radiological Health Neurological and Physical Medicine Devices division director Carlos Peña said: “This is an example of how innovative digital technologies can help provide patients access to additional tools during their treatment.

"Results indicated a statistically significant increase of 40.3% in adherence to abstinence for the patients who used Reset, compared to 17.6% in the standard treatment group."

“More therapy tools mean a greater potential to help improve outcomes, including abstinence, for patients with substance use disorder.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The FDA permit is based on the data obtained during a multi-centre, unblinded 12-week clinical trial performed in 399 subjects who received standard treatment in combination with the desktop-based version of Reset or standard treatment alone.

Results indicated a statistically significant increase of 40.3% in adherence to abstinence for the patients who used Reset, compared to 17.6% in the standard treatment group.

The Reset device is indicated as a prescription-only adjunct treatment for SUD patients who are not currently on opioid replacement therapy, and for people who do not solely abuse alcohol or opioids.